Antibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | -.--% | -.--% | -68.28% |
04-24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
04-19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.45M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- ATE Stock
- News Antibe Therapeutics Inc.
- Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul